Commercialization brings hurdles for bioconvergence investing
Bioconvergence products blur the lines between drugs, devices and software – and with them, the rules for getting to market.
Bioconvergence products blur the lines between drugs, devices and software – and with them, the rules for getting to market.
BELLINGS Intelligence Score: 15
Why it matters
The commercialization challenges in bioconvergence investing highlight emerging regulatory and market complexities but remain a niche issue with limited immediate impact on broad credit markets.
Sources
Venture Capital Journal
Commercialization brings hurdles for bioconvergence investing
Bioconvergence products blur the lines between drugs, devices and software – and with them, the rules for getting to market.